Publications

2020

Patel SS, Kluk MJ, Weinberg OK. NPM1 Biology in Myeloid Neoplasia. Curr Hematol Malig Rep. 2020;15(4):350-359.
Burkhart DL, Morel KL, Wadosky KM, Labbé DP, Galbo PM, Dalimov Z, et al. Evidence that EZH2 Deregulation is an Actionable Therapeutic Target for Prevention of Prostate Cancer. Cancer Prev Res (Phila). 2020;13(12):979-988.
Hashim D, Gonzalez-Feliciano AG, Ahearn TU, Pettersson A, Barber L, Pernar CH, et al. Family history of prostate cancer and the incidence of ERG- and phosphatase and tensin homolog-defined prostate cancer. Int J Cancer. 2020;146(10):2694-2702.
Zhang T, Na JH, Li S, Chen Z, Zhang G, Pang S, et al. Functional impact of cancer patient-associated Bcl-xL mutations. MedComm (Beijing). 2020;1(3):328-337.
Crowley L, Cambuli F, Aparicio L, Shibata M, Robinson BD, Xuan S, et al. A single-cell atlas of the mouse and human prostate reveals heterogeneity and conservation of epithelial progenitors. Elife. 2020;9.
Curty G, Beckerle GA, Iñiguez LP, Furler RL, de Carvalho PS, Marston JL, et al. Human Endogenous Retrovirus Expression Is Upregulated in the Breast Cancer Microenvironment of HIV Infected Women: A Pilot Study. Front Oncol. 2020;10:553983.
Ginter PS, McIntire PJ, Kurtis B, Mirabelli S, Motanagh S, Hoda S, et al. Adenomyoepithelial tumors of the breast: molecular underpinnings of a rare entity. Mod Pathol. 2020;33(9):1764-1772.
Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, et al. Author Correction: FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. 2020;585(7826):E20.
Herbst RS, Aisner DL, Sonett JR, Turk AT, Weintraub JL, Lindeman NI. Practical Considerations Relating to Routine Clinical Biomarker Testing for Non-small Cell Lung Cancer: Focus on Testing for RET Fusions. Front Med (Lausanne). 2020;7:562480.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700